Anna M. Serwotka-Suszczak
University of Wrocław
CytotoxicityImmunotoxinDrug carrierMolecular biologyCytotoxic T cellPeptide sequenceChemistryConjugateINTCysteineMTT assayAnti her2Monoclonal antibodyFlow cytometryBiochemistryStereochemistryCancer cell
3Publications
2H-index
26Citations
Publications 3
Newest
It has been brought to our attention that the affiliation of Dr. Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [...]
Source
#1Anna M. Serwotka-Suszczak (UWr: University of Wrocław)H-Index: 2
#2Alicja M. Sochaj-Gregorczyk (UWr: University of Wrocław)H-Index: 3
Last. Jacek Otlewski (UWr: University of Wrocław)H-Index: 44
view all 6 authors...
Antibody-drug conjugates (ADCs) have recently emerged as efficient and selective cancer treatment therapeutics. Currently, alternative forms of drug carriers that can replace monoclonal antibodies are under intensive investigation. Here, a cytotoxic conjugate of an anti-HER2 (Human Epidermal Growth Factor Receptor 2) diaffibody with monomethyl-auristatin E (MMAE) is proposed as a potential anticancer therapeutic. The anti-HER2 diaffibody was based on the ZHER2:4 affibody amino acid sequence. The...
10 CitationsSource
#1Alicja M. Sochaj-Gregorczyk (UWr: University of Wrocław)H-Index: 3
Last. Jacek OtlewskiH-Index: 44
view all 3 authors...
Abstract Targeted therapy is a new type of cancer treatment that most often uses biologically active drugs attached to a monoclonal antibody. This so called antibody-drug conjugate strategy allows the use of highly toxic substances that target tumor cells specifically, leaving healthy tissues largely unaffected. Over the last few years, antibody-drug conjugates have become a powerful tool in cancer treatment. We developed and characterized a novel cytotoxic conjugate against HER2 tumors in which...
15 CitationsSource